We studied lymphocyte recovery in 88 children who consecutively underwent unrelated cord blood transplantation for malignant (n 5 64) or nonmalignant (n 5 24) diseases. All children but 3 received myeloablative conditioning regimens with pretransplant antithymocyte globulin. Median age was 5.6 years (0.1-18 years) and median follow-up was 40 months (10-136 months). The median dose of infused viable CD45 1 cells (vCD45) was 3.35 Â 10 7 /kg with a ratio infused vCD45/collected total nucleated cell at 0.46. Immunologic endpoints were: time to achieve CD3
INTRODUCTION
Since initial studies reported by Kurtzberg et al. [1] , Wagner et al. [2] , and Gluckman et al. [3] , hematopoietic stem cell transplantation (HSCT) from an unrelated cord blood unit (UCBT) has become an accepted therapeutic strategy for children without an HLA identical donor who need an allogeneic HSCT [4] . The increasing use of CB, relative to bone marrow transplantation (BMT), in the unrelated donor setting is explained by such reasons as noninvasive hematopoietic collection, prompt availability of UCB units, less stringent criteria for HLA matching, lower incidence and severity of graft-versus-host disease (GVHD), and overall similar outcomes with both types of grafts in children [5] [6] [7] and adults [8, 9] . Despite the low incidence of GVHD, relapse rate of leukemia appears to be similar after UCBT or unrelated BMT [10, 11] . Nevertheless, UCBT remains associated with a high incidence of life-threatening infections, especially during the early posttransplant period [10, 12, 13] . Infection-related mortality is the major cause of nonrelapse mortality following UCBT, and is often directly related to delayed immune recovery [7, 14, 15] . Several reports have described lymphocyte subset reconstitution and factors affecting their speed of recovery after UCBT [16] [17] [18] [19] [20] . Although these studies constitute major contributions, their conclusions may be viewed as limited, owing to some of their features such as relatively low number of transplanted patients, patient selection leading to potential bias, and multicentric data resulting in heterogeneity of transplant procedures and evaluation of posttransplant immune recovery. Here, we report a detailed analysis of lymphocyte subset recovery homogeneously conducted in 88 children who consecutively received UCBT in a single pediatric transplant center.
MATERIALS AND METHODS

Patients
Patients treated in our pediatric transplant program were eligible for the study if they met all the following criteria: (1) having received HSCT with a single unrelated cord blood unit, (2) being 18 years old or less at time of transplant, (3) being in remission at the time of transplant for children with malignant diseases. Eighty-eight children consecutively transplanted between February 1997 and December 2007 fulfilled these criteria and were included in the study.
Evaluation of HLA Compatibility and Prefreezing Transplant Dose
Donor-recipient HLA matching was assessed at generic level for HLA-A and -B (ie, low/intermediate resolution molecular typing). High-resolution genotyping of HLA DRB1 of recipients and UCB was performed by polymerase chain reaction-sequence specific primer (PCR-SSP). HLA compatibility was expressed as the number of identical loci among 6.
CB units were obtained from CB banks located in France (n 5 45), the United states (n 5 18), Germany (n 5 7), the United Kingdom (n 5 5), Italy (n 5 5), Spain (n 5 4), Belgium (n 5 1), and Denmark (n 5 1), which provided the prefreezing total nucleated cell (TNC) dose for each unit.
Evaluation of Transplant Cell Dose and Quality Controls on Thawed CB
The infused transplanted cell doses were evaluated by the TNC count as well as by absolute CD34 1 and CD45 1 cells counts. Absolute counts of CD34 1 and CD45 1 cells were determined using the Stem-Kit numeration kit (Beckman-Coulter Company, Fullerton, CA), as previously described [21] . Briefly this commercially available diagnostic kit includes the viability dye 7-amino actinomycin D (7-AAD). Thus, the viable CD45 (vCD45) count corresponds to viable infused cells expressing the CD45 common leukocyte antigen. Including fluorescent microspheres, this single platform assay allows for a quantification of viable CD34 1 and CD45 1 cells (vCD34 1 and vCD45 1 , respectively) [22, 23] . Data acquisitions and analyses were performed on a FACSCalibur 4-color flow cytometer using the Cellquest software (Becton Dickinson Immunocytometry System [BDIS], San Jose, CA). The gating strategy is adapted from ISHAGE guidelines following recommendation for cord blood CD34 cell enumeration [22] . 
Evaluation of Lymphocyte Subsets
Endpoints
Standard definitions were used for common posttransplant endpoints, namely, overall survival (OS), relapse incidence, treatment-related mortality (TRM), acute GVHD (aGVHD), and chronic GVHD (cGVHD). Several immunologic endpoints were chosen for their potential clinical significance: time to achieve a CD3 
Statistical Methods
November 1, 2008, was used as the reference date, that is, the day when we locked data on patient outcomes. As for OS, Kaplan-Meier estimates provided estimated incidence over time. However, the other endpoints shared a competing risk setting, meaning patients could develop events that avoid the occurrence of the event of interest. As an example, after death or relapse before achievement of an immunologic endpoint, no further immunologic recovery could occur. Therefore, these endpoints (TRM, relapse, and all endpoints used for assessment of immunologic recovery) were analyzed through the use of cumulative incidence curves for estimating incidence over time [24] and through Fine and Gray models [25] to assess prognostic factors. In this study, TRM, relapse, infusion of a stem cell rescue, and autologous recovery were considered as competing risk for immunologic recovery.
Variables studied for their potential impact on lymphocyte recovery included recipient age, weight, sex, pretransplant cytomegalovirus (CMV) serology, disease (malignancy or not), graft-recipient HLA match (6 or 5 of 6 versus less), graft cell dose, conditioning regimen (with or without total body irradiation [TBI]), and aGVHD. These variables were tested in the univariate analysis as well as in the multivariat models. Cause-specific hazard ratios (HR) were estimated with 95% confidence intervals (95% CI).
Among variables studied for their potential impact on lymphocyte recovery, graft cell dose was described by 5 related variables: collected and infused TNC, infused viable CD34
1 and CD45 1 cell dose, and infused CD3 1 cell dose. Therefore, the influence of transplant cell dose was investigated by performing 5 different multivariate analyses, each of these analyses using 1 of the variables described. Additionally, Spearman rank correlation coefficient was used to estimate correlation between these 5 related variables. Unlike all other studied variables, aGVHD cannot be defined at the time of transplantation and can occur until day 100. Consequently, the impact of aGVHD on immunologic recovery required a specific statistical analysis beginning at day100 posttransplant.
All statistical analyses were performed using the SPSS version 15.0.1 (SPSS Inc., Chicago, IL) and the R 2.7.2 software package; the cumulative incidence function has been estimated using the cmprsk package. 
RESULTS
Patients and Cord Blood Characteristics
Transplantation Procedure
All children but 3 received a myeloablative conditioning regimen with either TBI (12 grays in 3 days and 6 fractions) and cyclophosphamide (60 mg/kg/ day for 2 days) (n 5 49), or busulfan and cyclophosphamide (50 mg/kg/day for 4 days) (n 5 36). In all cases, antithymocyte globulin (ATG) (rabbit ATG, Thymoglobine Ò ) was infused at a dose of 2.5 mg/kg/ day from days 23 to 21. GVHD prophylaxis uniformly consisted of cyclosporine A (CsA) and methylprednisolone (from day 25 to day 5: 1 mg/kg/day; 1.5 mg/kg/day through days 18; 1 mg/kg/day through day 25; 0.75 mg/ kg/day through days 32; 0.5 mg/kg/day through days 39; 0.25 mg/kg/day through days 45 and stop). Children with malignant diseases and nonmalignant disorders received CsA for a total duration of 3 and 6 months, respectively. aGVHD was treated with steroids. Granulocyte colony-stimulating factor was administered after transplantation to all patients.
Global Outcomes
The median follow-up period was 40 months (range: 10-136). Probability of 1-year and 5-year OS were 69% 6 5.2% and 62% 6 4.1%, respectively. TRM was 19.7% 6 4.3%. Causes of death were relapse (n 5 13), infections (n 5 11), GVHD (n 5 2), multisystem organ failure (n 5 2), veno-occlusive disease (n 5 1), and heart failure (n 5 1). The median time to reach 
Lymphocyte Subsets Recovery
These outcomes are shown using cumulative incidence curves (Figure 1) .
Most of the patients reached the NK and B cell endpoints: 69 and 62 patients, respectively. NK cells recovered first with a median time to reconstitution of 33 days and an IQR from 31 to 60 days, whereas median time to B cells reconstitution was 97 days (IQR: 68.5-144.8) (Figure 1A and B) .
T cell recovery was slower ( Figure 1C ). Fifty-six children achieved the early endpoint (CD3 .500/ mm 3 ) and 42 patients the latest one (CD3 .1500/ mm 3 ). Cumulative incidence estimates showed that the median time to reach these endpoints were 214 days (IQR: 131-266) and 340 days (IQR: 254.8-404.8), respectively. The reconstitution of CD8 1 T cells appeared to be faster than CD4's recovery ( Figure 1D ).
Factors Affecting Lymphocytes Recovery
The results of univariate and multivariate analyses are shown in Table 2 .
In the multivariate analysis, infused vCD45 cell dose (as a continuous variable) clearly improved the early endpoint for T cell recovery (CD3 .500) with an HR multiplied by 1.14 fold per 1 Â 10 7 vCD45/kg increment (P 5 .014), the CD4 (HR: 1.12, P 5 .032), and the NK cell reconstitution (HR: 1.17, P 5 .033). With patients grouped according to viable CD45 cell dose quartiles, more rapid recovery occurred in recipient of more than 3.35 Â 10 7 /kg CD45 cell after thawing of CB unit (Figure 2 ). This statistical correlation was observed for early CD3 reconstitution (HR: 2.18, P 5 .003) and for CD4 reconstitution (HR: 2.33, P 5 .0036) (Figure 2B and D) .
As shown in Figure 3 , vCD45 cell dose was statistically correlated with all 4 other variables used in this study to describe graft cell dose, that is, collected TNC, infused TNC, CD34
1 , and CD3 1 cell doses (P \.01 for each correlation). However, the influence of graft cell dose on T cell recovery was no longer statistically significant when collected TNC, infused TNC CD34
1
, or CD3
1 cell doses were used in the model instead of the infused vCD45 cell dose.
When the late endoint for T cell recovery was analyzed (CD3 \1500), we observed a better reconstitution when age recipient was younger (HR: 0.91 for each additional year of age, P 5 .013). None of the variables showed a significant influence on CD8 cell reconstitution. A negative pretransplant CMV serology was associated with an improved B cell recovery of B cells (HR: 1.92, P 5 .019). NK cell reconstitution was more rapid in children with malignant diseases than in children without malignancies (HR: 1.97, P 5 .034). Finally, occurrence of aGVHD had no apparent influence on immune cell recovery.
DISCUSSION
Several studies have previously described lymphocyte subset recovery after unrelated CBT [16] [17] [18] [19] [20] . Nevertheless, our study may improve the understanding of this process through 3 methodologic characteristics. (1) We stuck to a homogeneous cohort of 88 children who consecutively underwent UCBTs, without any further selection based on survival duration or relapse occurrence. The other series reported lymphocyte recovery of smaller cohorts with more selected patients, the larger study being the Eurocord cohort, which included 49 UCBT recipients [20] . (2) These 88 UCBTs were carried out in a single pediatric transplant unit, which established relatively good homogeneity for transplant procedures, notably CB unit selection and manipulation, biologic controls performed on the thawed and infused UCB, conditioning regimen, GVHD prevention, supportive care, and immune monitoring in transplanted patients. (3) Lymphocyte recovery is subject to competing risks. Therefore, we analyzed our data using cumulative incidence curves for estimating incidence over time in the presence of competing risks [24] [25] [26] as recommended by European Group for Blood and Marrow Transplantation [27] . This method gives a more accurate estimation of endpoint sharing competing risks than the KaplanMeir method, which is known for overestimating real probabilities in this context, particularly when the event of interest occurs late after transplant. Indeed, this kind of statistical approach of competing risk is currently the standard method for evaluating TRM and relapse after HSCT and is increasingly used to describe granulocyte and platelet reconstitution [27] . Using such a methodology implies the choice of thresholds to describe immunologic endpoints. The use of normal values is not a suitable solution because normal values in children are highly dependent on the age, and because this agerelated variability has probably not the same clinical relevance after UCBT. In fact, in this situation, stem cells definitely rise from newborn blood, regardless of recipient age. Moreover, immunologic efficiency does not necessarily mean complete immunologic reconstitution. In this study, we decided to chose 2 endpoints for CD3
1 T cell reconstitution: (1) CD3 .500/mm 3 as a relatively early event; (2) CD3 .1500/mm 3 as a later endpoint. Other thresholds for lymphocyte recovery were chosen close to the lower limit of adult normal values [28, 29] .
In our study, lymphocyte recovery followed the same sequence as in previous studies: NK cells first, then B cells, whereas T cells reconstituted later [16] [17] [18] [19] [20] . CBT as in other stem cell transplantation, the innate immune system appears to recover much earlier than adaptative immunity. In our series of patients, median time to recovery for both neutrophil and NK cells was 30 days, similarly to previously reported data [3, 12] .
B cells recovered within a median of 3 months posttransplant, whereas Thomson et al. [16] and Niehues et al. [20] reported a normalization of the B cell count after as late as 6 months. This might just reflect differences in the definition of endpoints. Indeed, the Eurocord study measured the time required to reach the age-related normal value, whereas we chose to study earlier endpoints for B cells as well as for T cells recovery. Among all factors evaluated in our study for their influence on B cell recovery, only the recipient pretransplant CMV serology proved significant, with an adverse effect in CMV positive recipients. To our knowledge, this association had been reported only once in a study by Kalwak et al. [30] . They observed that CMV reactivation impaired B cell recovery in allogeneic BMT recipients with GVHD. Whether CMV status directly influences restoration of B lymphopoiesis, however, remains unclear because early preemptive antiviral therapy might also adversely affect immune reconstitution.
As in all previously published papers, T lymphocyte subsets were the last ones to recover. In our study, this delay could be worsened by the use of ATG in the immune suppression regimen. Several studies have demonstrated that ATG given pretransplant are still active in the early posttransplant period and could therefore interact with immune recovery [31] . Reconstitution of T cells after allogeneic HSCT proceeds through 2 pathways. The early thymic-independent pathway includes the antigen-driven expansion of peripheral donor T cells, leading to limited TCR diversity [32] . The late thymic-dependent pathway involves selection of graft-derived lymphocyte precursor cells generating a full T cell repertoire [33, 34] . Our study shows the influence of age on the latest T cell recovery endpoint (CD3 .1500), which is supposed to reflect particularly the thymic-dependent pathway. Young recipients had a better T cell recovery than older, probably reflecting the age-related decline of thymic function [33] . We also showed that the number of viable CD45 cells was the most important factor for the early T cell endpoint (CD3 .500) and for CD4 recovery. Among graft cell doses, neither collected TNCs, nor infused TNC, nor infused CD34 cells were found to significantly alter lymphocyte recovery, whereas these criteria are well-identified determinants of hematopoietic reconstitution after UCBT [3, 5, 21, 35, 36] . Several hypotheses can be made to explain this apparent discrepancy. It is possible that the vCD45 cell dose, which reflects the viable infused cells expressing the common CD45 leukocyte antigen, may be a more potent criteria to predict engraftment than the TNC count, which includes nonviable cells and mature erythroblasts. The high collected and infused TNC dose in our study, which are 7.1 and 5.35 Â 10 7 /kg, respectively, could also have contributed to the lessening of the impact of this criterion by decreasing the number of transplants with very low cell dose and a very high risk of graft failure. Finally, one could argue that criteria and thresholds defined to predict hematopoietic engraftment are not necessarily adequate when the endpoint is immunologic recovery.
Our study suggests that a minimum vCD45 cell dose of 3.35 Â 10 7 /kg at infusion must be targeted to achieve a faster lymphocyte reconstitution. Thus, vCD45 count might be used as a predictive factor for quality of T cell recovery and consecutively for the risk of life-threatening infections [37, 38] . However, our findings are only based on the quantitative recovery of lymphocyte subsets and not on qualitative data such as specific functional T cell responses to opportunistic agents and evaluation of thymic output. This is an evident limitation of the study, which reduces its potential implications on our knowledge of posttransplant infection risk factors and infectionrelated mortality. Further studies are required to better describe relationships between post-UCBT lymphocyte subset recovery, immune function, infectious complications, and survival.
Criteria for CB unit selection are currently based on hematopoietic engraftment targets. All studies strongly advised the use of a high cell dose, the minimal cell dose recommended for transplantation usually ranging from 2.5 to 4 Â 10 7 collected TNC/kg [3, 12, 39] , or at least 1.7 Â 10 5 CD34 cells/kg [21, 36] . If our observations were confirmed, it would imply choosing larger CB units. Indeed, in our study, the amount of viable CD45 represented 46% of cryopreserved TNCs. Aiming at this threshold of 3.35 Â 10 7 /kg at infusion therefore would imply selecting grafts containing at least 7.2 Â 10 7 TNC/kg at collection. From a clinical point of view, this goal is very difficult to achieve with a single unit because CB cell doses are intrinsically limited by the amount of cells in the placenta. Moreover, narrowing selection criteria to get a larger transplant might force selection of less well-matched units, with the risks associated with higher mismatching. To achieve such a CD45 threshold, several possibilities must be investigated, such as double cord blood transplantation or ex vivo expansion of UCB. Concerning ex vivo expansion of UCB, preclinical data are yet too preliminary to assess its efficacy in terms of hematopoietic and immune recovery [40, 41] . Recent reports on double-unit UCBTs have suggested better engraftment, more GVHD, less relapse, and better survival than after single-unit UCBTs [42] [43] [44] [45] [46] . Whether or not doubleunit transplantations may improve immunologic recovery is an essential question that requires further investigations.
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